M

Mural Oncology PLC
NASDAQ:MURA

Watchlist Manager
Mural Oncology PLC
NASDAQ:MURA
Watchlist
Price: 2.04 USD Market Closed
Market Cap: 35.4m USD

Mural Oncology PLC
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Mural Oncology PLC
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
M
Mural Oncology PLC
NASDAQ:MURA
Research & Development
-$110.7m
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Alkermes Plc
NASDAQ:ALKS
Research & Development
-$283.3m
CAGR 3-Years
9%
CAGR 5-Years
10%
CAGR 10-Years
1%
Amarin Corporation PLC
NASDAQ:AMRN
Research & Development
-$20.4m
CAGR 3-Years
13%
CAGR 5-Years
13%
CAGR 10-Years
9%
Prothena Corporation PLC
NASDAQ:PRTA
Research & Development
-$170.4m
CAGR 3-Years
-12%
CAGR 5-Years
-20%
CAGR 10-Years
-13%
No Stocks Found

Mural Oncology PLC
Glance View

Market Cap
35.3m USD
Industry
Biotechnology

Mural Oncology PLC is a IE-based company operating in Biotechnology industry. Mural Oncology plc is a clinical-stage oncology company. The firm is leveraging its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. The company leverages its expertise in cytokine biology, immune cell modulation and protein engineering capabilities to develop immunotherapies. The firm is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. Its portfolio of programs includes Nemvaleukin alfa (Nemvaleukin)-IL-2, IL-12, and IL-18. Nemvaleukin is an engineered interleukin-2 (IL-2) variant designed to harness the potent anti-cancer capabilities of high-dose rhIL-2 while minimizing toxicity by selectively activating cancer-fighting CD8 T cells and NK cells. The tumor-targeted split IL-12 program focuses on delivering the therapeutic potential of IL-12 by splitting it into inactive component.

MURA Intrinsic Value
8.33 USD
Undervaluation 76%
Intrinsic Value
Price
M

See Also

What is Mural Oncology PLC's Research & Development?
Research & Development
-110.7m USD

Based on the financial report for Dec 31, 2024, Mural Oncology PLC's Research & Development amounts to -110.7m USD.

What is Mural Oncology PLC's Research & Development growth rate?
Research & Development CAGR 3Y
12%

Over the last year, the Research & Development growth was 33%. The average annual Research & Development growth rates for Mural Oncology PLC have been 12% over the past three years .

Back to Top